Walleye Capital
RGNX icon

Walleye Capital’s Regenxbio RGNX Stock Holding History

Walleye Capital’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,100
Closed -$209K – 1526
2019
Q4 		$209K Buy
5,100
+200
+4% +$7.9K 0.01% 1089
2019
Q3 		$174K Buy
+4,900
New +$199K 0.01% 1251

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Walleye Capital's RGNX Position: Q2 2026 in Review

Walleye Capital opened a new position in Regenxbio (RGNX) in Q2 2026: 203,726 shares worth $2.44M. The stake represents 0.01% of the portfolio and ranks #1349 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RGNX as recently as Q4 2024.

Walleye Capital first reported a position in RGNX in Q3 2021 and has held it in 5 quarters since. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Walleye Capital held 203,726 shares of Regenxbio worth $2.44M as of Q2 2026.
  • Regenxbio was a new Walleye Capital position in Q2 2026.
  • Regenxbio made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1349 holding.
  • Walleye Capital first reported a position in Regenxbio in Q3 2021 and has held it in 5 quarters since.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.